Programme

Topic II: What can we contribute to world cancer community in Taiwan?

熱烈歡迎TTBA 2024十週年年會第一位Keynote Speaker – Dr. Eric Chuang

大家是否迫不及待知曉年會重磅邀請的講者了呢！TTBA特別從台灣邀請來目前在工研院擔任副總暨所長的莊曜宇博士

莊博士可謂『跨領域』的代表，從美國國家癌症研究所(NCI) 放射科學主任轉任回台後，先後專攻生物晶片定序、生醫資訊、人工智慧等研究領域，爾後鑽研商業模式與企業管理，近年更旋風轉任工研院副總並精準掌控生醫業界脈動，充分實踐『跨界力』的影響！

莊博士將分享在其精彩豐富的職涯中，如何斜槓跨足各領域並游刃有餘，在學界、業界同時大放異彩！

Warmly welcome TTBA 2024 Annual Conference Keynote Speaker – Dr. Eric Chuang

Are you excited to find out about the prestigious speaker for this year's symposium? TTBA is honored to invite Dr. Eric Chuang as our keynote speaker and guest

Biography：

Dr. Chuang earned his Sc.D. in Cancer Biology from Harvard University in 1997, with additional studies in Toxicology and Molecular Genetics. He continued his cancer research with a postdoctoral fellowship at Harvard. He later joined the National Cancer Institute (NCI) at the National Institute of Health (NIH) as a fellow, where he worked on radiation genomics. He has led the NCI’s Radiation Oncology Program in the Cancer Treatment and Diagnosis Department, overseeing a series of research grants at the NIH, including studies on radiation-induced signaling pathways, molecular mechanisms, normal tissue damage, and radiation-related gene research. In 2011, Dr. Chuang returned to National Taiwan University (NTU) and became the Director of the Graduate Institute of Biomedical Electronics and Bioinformatics at NTU. In his research career, Dr. Chuang has published 160 peer-reviewed articles and has notable experience as an editorial board member for scientific reports and as the editor-in-chief of Translational Cancer Research.

Topic I: Biomedical big data and AI: Current status & future development in Taiwan

TTBA 2024十週年年會大咖講者持續登場！接下來要介紹的是第二位Keynote Speaker – Dr. Mien-Chie Hung🎊

TTBA十週年年會重磅邀請到洪明奇院士重返德州開講❗❗

洪院士目前為中國醫藥大學校長、中研院院士。在美國深耕四十餘年間，他曾擔任美國德州大學安德森癌症中心基礎研究副院長、分子與細胞腫瘤學系主任及傑出講座教授，並於2023年當選為世界科學院（TWAS）院士。洪校長在癌症基礎科學研究上取得了卓越的成就，並將其成功應用於臨床轉譯領域，為癌症醫學做出了重大貢獻，根據 Research . com 2024最新排名，洪校長榮登台灣醫學科學家及台灣分子生物科學家榜首，可謂台灣之光！不論你需要洪校長留美多年的經驗分享或是其對台灣就業資源與學界現況的精準剖析，這次的演講必定都會令你受益良多，千萬別錯過！

📌Warmly welcome TTBA 2024 Annual Sympoisum Keynote Speaker – Dr. Mien-Chie Hung 🔥

Biography：

Mien-Chie Hung, Ph.D. is the President of China Medical University in Taiwan. He was the vice president for basic research, the founding chair of the Department of Molecular and Cellular Oncology, and a Distinguished Endowed Chair at The University of Texas MD Anderson Cancer Center. He is a basic scientist with a translational vision and has significantly contributed to understanding the biology of receptor tyrosine kinases in cancer and developing combinational cancer therapies to overcome drug resistance. His lifetime h-index reaches 172 (Google). He served as a member of the Tang Prize Selection Committee. He was inducted as an Academician of the Academia Sinica in Taiwan in 2002, a Fellow of AAAS in 2010, and a TWAS member in 2023.

【📌年會講者介紹—學界篇】TTBA 十週年年會 Academia Session—千萬別錯過的學術交流🥂

分享本次TTBA年會的Academia Session，我們很榮幸邀請到三位在學界不同領域的專家學者：

🎤 Dr. Hui-Wen Lo: 轉譯癌症研究🔬 教授@UTHealth Science Center at Houston

🎤 Dr. James Cai: 機器學習、單細胞計算生物學💻 教授@Texas A&M University

🎤 Dr. Danny Chou: 內分泌、代謝生物醫學教授 & 生醫界KOL🤩 生醫不科科：研究×生活@Stanford University

三位學者都將在年會的Academia Session將自己多年在學界闖蕩的歷程、各自的研究專業/領域，經營生醫相關社群媒體的經驗，以及如何撰寫一份成功的Grant申請資料等，通通不藏私地與大家分享！期間當然還包括了與講者們近距離的互動與Networking！還有能夠接觸到在醫學中心進行學術研究的機會哦！

目前在學界、未來想繼續往學界發展的朋友們，這場講座的內容絕對讓各位感到不虛此行，趕快手刀報名吧！

Hello everyone! We are excited to share a special session at this year’s TTBA Annual Symposium—the panel discussion featuring prominent scholars from academia. We have invited three distinguished speakers:

🎤 Dr. Hui-Wen Lo, expert in translational cancer biology and metastatic brain tumor at UT Health Science Center at Houston

🎤 Dr. James Cai, expert in Bioinformatics, machine learning, single-cell computational biology at Texas A&M University

🎤 Dr. Danny Chou, expert in endocrinology and diabetes, insulin therapeutics at Stanford University

They will share their extensive experiences in academia, provide insights into research opportunities at the Texas Medical Center, discuss cancer-related topics, and offer tips on crafting a successful grant application! Of course, there will also be ample opportunity for close interactions and networking with the speakers and experts from similar fields!

For those currently in academia or planning to pursue an academic career, this session will be incredibly beneficial for your professional development. Don’t miss out—register now!

Biography：

Dr. Hui-Wen Lo is a seasoned basic and translational cancer biologist and a leader in the areas of primary and metastatic brain tumors, as well as, metastatic breast cancer. Her research program is robust and supported by multiple funding agencies, including NCI, DoD, and other agencies. She has published more than 110 peer-reviewed publications. Dr. Lo is a dedicated educator and mentor who has trained many trainees in her previous institutions Duke University School of Medicine and Wake Forest School of Medicine, and currently trains multiple trainees. In addition to her scholarly activities, Dr. Lo has been serving in many leadership roles. Previously at Wake Forest School of Medicine, she served as the Associate Director for Shared Resources Management and Associate Director for Basic Sciences for the NCI-designated Wake Forest Baptist Comprehensive Cancer Center. In that role, she led three research programs, coordinated interprogrammatic collaborations, and contributed to the successful renewal of the NCI Cancer Center Support Grant in 2022. At her current Institution of McGovern Medical School, the University of Texas Health Science Center at Houston, she continues to play multiple leadership roles as the Director of the Metastatic Brain Tumor Program and the Vice Chair of Research in the Department of Neurosurgery, the home of 18 PhD faculty and 12 physician-scientists. Dr. Lo has brought in multiple grants with >5 million dollars to her current institution since September 2022. Her laboratory continues to focus on the biology and treatments of hard-to-treat human cancers.

Dr. James Cai is a Professor of Computational Systems Biology with a joint appointment in the Veterinary Integrative Biosciences and Electrical & Computer Engineering departments at Texas A&M University. His research integrates genomics, computational statistics, and data science, employing machine learning, graph theory, and quantum computation to understand cellular behaviors. Dr. Cai has made significant contributions to the field of single-cell computational biology, including developing the easy-to-use desktop application for single-cell gene expression analysis without programming, and advanced machine learning methods such as scTenifoldXct for predicting cell-cell interactions, scTenifoldKnk for performing virtual gene knockouts, and scTenifoldNet for constructing and comparing single-cell gene regulatory networks. He also introduced QuantumGRN, a quantum circuit model for inferring gene regulatory networks. With expertise in data science, machine learning, and quantum computing, Dr. Cai's interdisciplinary research contributes to our understanding of cellular behavior and genetic disease mechanisms, shaping future diagnostic and therapeutic strategies.

Dr. Danny Chou is an Associate Professor of Pediatrics (Endocrinology and Diabetes) and by courtesy, of Chemical & Systems Biology at Stanford University. He received his PhD from Harvard University in 2011. He then moved to MIT, where he was a JDRF Postdoctoral Fellow in the Department of Chemical Engineering. Danny started his independent career at the University of Utah in 2014. At Utah, Danny's research focused on protein and peptide therapeutics for the treatment of Type 1 Diabetes and other human diseases. In 2020, Danny moved his research lab to Stanford University to continue their efforts in developing novel insulin therapeutics. Danny has received recognitions including an American Peptide Society Early Career Lectureship, Boulder Peptide Society Young Investigator Award, JDRF Career Development Award, Vertex Scholar, JDRF Postdoctoral Fellowship, ADA Junior Faculty Award, and an NIDDK Catalyst Award.

【📌年會講者介紹—業界篇】TTBA 十週年年會 Industry Session— 一窺大藥廠的藥物開發流程🧪

近期火紅的輝達執行長黃仁勳認為，在電腦科學之後，生命科學將是最具潛力的產業，尤其藥物的開發在AI幫助下更是如虎添翼。因應"AI教父"的開示，我們很榮幸邀請到四位擁有豐富大藥廠經歷的專家出席本次TTBA年會的Industry Session：

🎤 Dr. Hsiao-Ling Hung: 臨床試驗與醫藥法規💊 Regulatory Consultant & 退休生技二姐在美國 & President @ Taiwanese American Association of Biotechnology (TAAB - 台美生技協會)

🎤 Dr. Yi-Hsiang Hsu: 蛋白質藥物開發與大數據標靶探索🤖 Vice President @ Profound Therapeutics & Associate Professor @ Harvard Medical School

🎤 Dr. YenRu Pan: 生物製劑製程開發🧫 Associate Director @ Gilead Sciences

🎤 Dr. Shu-Hong Lin: 資料科學及機器學習應用於標靶開發 🖥️ Senior Scientist @ BioNTech

四位專家的分享將涵蓋從藥物開發的前期標靶探索、臨床試驗前的製程開發，以及臨床試驗後的醫藥法規。豪華的講者陣容中，將談談從bench scientist 轉職醫藥法規，如何同時跨足學界與藥廠，以及大藥廠與新創生技公司之間差異，本次講座正是與這些專家討教的大好機會！

對於美國生技產業和藥物開發有興趣、未來想投入藥廠生技公司的朋友們，絕對不該錯過這場講座，趁現在趕快報名吧！

TTBA 10th Annual Symposium - Industry Session 🧪

Jensen Huang, Nvidia CEO, believes life science will be the future star after computer science. Drug discovery and development, especially, has been accelerated by the rise of AI. Given this trend, We invited four speakers experienced in drug discovery and development to attend the panel discussion featuring experts in biotech industry at this year’s TTBA Annual Symposium:

🎤 Dr. Hsiao-Ling Hung: Regulatory strategies for drug development. Regulatory Consultant & President, Taiwanese American Association of Biotechnology

🎤 Dr. Yi-Hsiang Hsu: Leveraging multi-omics for target discovery and identification. VP @ Profound Therapeutics Director and Associate Professor @ Harvard Medical School

🎤 Dr. YenRu Pan: Biologics process development. Associate Director @ Gilead Sciences

🎤 Dr. Shu-Hong Lin: Data Science and machine learning in target discovery for TCR T cell therapy. Senior Scientist @ BioNTech

Their talks will cover several processes of drug development, including target discovery, process development, regulatory affairs after clinical trials, and moreover, the application of AI. It’s a great opportunity to learn from these experts!

Biography：

Dr. Hsiao-Ling Hung is currently an independent consultant providing regulatory strategy services to over 20 biopharmaceutical companies, and President of Taiwanese American Association of Biotechnology.

Her past professional experience includes Senior VP, RA/QA at Ambrx, a public clinical-stage biotech company that focuses on developing Engineered Precision Biologics, Sr Director in Global Regulatory Sciences at BMS, leading regulatory strategy and managing regulatory staff for the Opdivo portfolio, Director of US and International Regulatory Affairs at Johnson & Johnson in Oncology and Immunology.

Prior to a career in regulatory affairs, Hsiao-Ling was a preclinical scientist for over 20 years, leading the discovery and preclinical research programs of compounds across multiple therapeutic areas.

Hsiao-Ling received a B.S. in Medical Technology from the National Taiwan University and a Ph.D. in Pathology and Molecular Biology from the University of Pennsylvania.

Dr. Yi-Hsiang Hsu is a Vice Presdient at Profound Therapeutic and also an Associate Professor of Medicine at Harvad Medical School. His research interests include 1) genetic contribution of common aging relevant disorders using population-based next generation whole genome sequencing, exome-sequencing and GWAS approaches; 2) statistical method development on multiple-phenotype association analyses; and 3) identifying biomarkers of osteoporosis using metabolomics. He received his BS from Taipei Medical School, Taiwan. He then pursued his MS in Epidemiology at National Taiwan University and received ScD from Harvard School of Public Health. Before he became the VP at Profound Therapeutic, he served as a Scientific Director at Amgen.

Dr. Pan leads the Rapid Testing Team, supporting the entire Biologics Development Organization for drug substance and drug product development testing activities at Gilead Sciences. Being passionate about innovation, she delivered the cell line technology development for the Gilead-format bispecific modality, designed tool cell lines for CAR T-

cell therapy analytical testing, and expanded biologics development testing capability and capacity via establishing next-generation cell line and process analytics. She also collaborates with the Data Sciences Team to increase cross-functional workflows’ operational efficiency. Dr. Pan obtained her Ph.D. degree in Biochemistry at UC-Irvine,

followed by a post-doctoral fellowship at the Scripps Research Institute.

Dr. Shu-Hong Lin is a versatile computational scientist with a passion for leveraging cutting-edge technologies to drive innovation in biotechnology. Based in Cambridge, MA, Dr. Lin holds a Ph.D. in Cancer Biology with a focus on Biostatistics, Bioinformatics, and Systems Biology from the University of Texas MD Anderson Cancer Center. With a proven track record in academia, government, and industry, Dr. Lin has honed his expertise in bioinformatics, epidemiological methods, and machine learning. His career highlights include roles such as Senior Scientist in Computational Biology at BioNTech US, where he spearheaded the integration of diverse datasets to drive early discovery of targets for TCR T cell therapy. He also played a crucial role in the development of RNA translatability predictors using pre-trained neural network models. Previously, as a Postdoctoral Fellow at the National Cancer Institute, Dr. Lin contributed to research on the safety of nucleoside reverse transcriptase inhibitors (NRTI) and explored the link between somatic mosaicism and infectious disease risk. His work has resulted in numerous publications in prestigious journals, showcasing his commitment to advancing scientific knowledge.

【📌年會講者介紹—AI&生物資訊篇】TTBA 十週年年會 AI & Bioinformatics Session— 當人工智慧遇上生物學🖥️

你也使用過當紅的Chatgpt嗎？不論你只是用Chatgpt回答問題，或是使用其AI繪圖功能（小編OS:甚至是讓它幫你寫年會宣傳文)，都不可否認AI的便利，以及它將成為全球產業的主流。今天要分享本次TTBA年會的AI & Bioinformatics Session，我們很榮幸邀請到四位在藥廠及學術界的AI及生物資訊領域專家：

🎤 Dr. Sabrina Hsueh: 藥廠AI監管部門 💻director @ Pfizer

🎤 Dr. Yu-Chiao (Chris) Chiu: 癌症基因體與藥物基因體的AI應用💊 助理教授 @ University of Pittsburgh

🎤 Dr. Kuan-Lin Huang: 機器學習與多體學算法🧬 助理教授 @ Icahn School of Medicine at Mount Sinai / 共同創辦人@ Open Box Science

🎤 Dr. Pei-Hua (Candice) Chu 獸醫學的AI應用 & 生醫界KOL🤩(朱珮華獸醫美國臨床病理教授) 🩺 助理教授 @ Texas A&M University

四位專家將分享如何將人工智慧、機器學習融入傳統生物學及獸醫醫學，且帶來更快速且精準的藥物開發或是蛋白質預測，以及大藥廠如何監督AI的使用。本次講座正是與這些AI專家Networking的大好機會！

目前致力於AI及生物資訊、或者是未來想朝這些領域發展的朋友們，絕對不該錯過這場講座，趕快報名吧！

TTBA 10th Annual Symposium - AI & Bioinfo Session 🖥️

Hi folks! We are excited to share a special session at this year’s TTBA Annual Symposium — the panel discussion featuring experts in AI & bioinformatics. Four distinguished speakers are invited from both biotech company and academia:

🎤 Dr. Sabrina Hsueh: expert in Responsible AI. Director of Ethical AI and External Innovation, Pfizer

🎤 Dr. Yu-Chiao (Chris) Chiu: expert in bioinformatics, machine learning, cancer genomics, and pharmacogenomics. Assistant professor of Medicine, University of Pittsburgh

🎤 Dr. Kuan-Lin Huang: expert in statistical genetics, DNA-sequencing (DNA-Seq) studies, proteomic biomarkers, multi-omic algorithm. Assistant Professor, Icahn School of Medicine at Mount Sinai / Co-Founder of Open Box Science

🎤 Dr. Pei-Hua (Candice) Chu: expert in bioinformatics, digital cytology, and artificial intelligence in veterinary medicine. Assistant Professor, Texas A&M University

They will share how they apply AI and machine learning to biology, which brings about faster and more precise ways to perform drug discovery or DNA and proteins. Moreover, they will teach us how to use AI properly and ethically. It’s a great opportunity to network with these experts.

Biography：

Sabrina Hsueh, PhD, FAMIA, is a trailblazing Ethical AI and External Innovation Lead at Pfizer, renowned for driving health AI innovations and responsible AI practices in healthcare and life sciences. She fosters the integration of AI and medicine across the end-to-end pipeline of AI innovation and adoption with a focus on humanity and equity. As a thought leader, Dr. Hsueh actively contributes to private-public partnerships, such as the NIST AI Safety Consortium, and leads community efforts to shape AI standards, including the IEEE P7008 Standards on AI Nudging and Real-World Data and Model Labels for AI.

An influential community leader, Dr. Hsueh serves on the Practitioner Board of the Association of Computing Machinery (ACM) and chairs the AI Evaluation Showcase at the American Medical Informatics Association (AMIA). She co-chairs the Trustworthy AI/Real-World Data for AI Work Group with Harvard Medical School DCI-Network, where stakeholders collaboratively develop guidelines for the responsible use of AI and understanding the pathways to AI governance. Previously at IBM Research, Dr. Hsueh led the Health Informatics Community, was elected into the IBM Academy of Technology, and actively contributed to scientific committees and workgroups in health informatics and data science.

A prolific author, Dr. Hsueh has published over 80 technical papers and patents, including the textbook “Personal Health Informatics: Patient Participation in Precision Health.”; She is deeply committed to mentoring the next generation of multi-disciplinary AI innovators, leading the Women in AMIA Steering Committee, co-hosting the ACM/AMIA podcast series, and co-founding a special interest group with IMIA/WHO to advance global health equity.

Dr. Yu-Chiao (Chris) Chiu is an Assistant Professor of Medicine in the Division of Oncology and the UPMC Hillman Cancer Center at the University of Pittsburgh. His research interests include bioinformatics, machine learning, cancer genomics, and pharmacogenomics. The goal of his laboratory is to systematically model genomics and pharmacogenomics to gain a better understanding of cancer biology and improve cancer therapy. Dr. Chiu has been honored with the prestigious NIH/NCI K99/R00 Pathway to Independence Award for his work in developing deep-learning methods to predict the responses of cancer cells to treatments. Since joining the University of Pittsburgh in 2022, he has received five research awards from the NIH Office of the Director, the Pittsburgh Liver Research Center, the UPMC Hillman Cancer Center, and the Leukemia Research Foundation. Furthermore, he was named a Hillman Early Career Fellow for Innovative Cancer Research. To date, Dr. Chiu has published more than 50 journal articles and 70 conference articles/abstracts. He is an active member of the bioinformatics community and has chaired sessions at the IEEE BIBM and ICIBM conferences. He serves as an Organizing Committee member for the IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI) in 2023 and 2024.

Born and raised in Taiwan, Kuan-lin “Kuan” Huang is an Assistant Professor of Genetics and Genomic Sciences & Artificial Intelligence. He leads the Precision Omics Lab at the Icahn School of Medicine at Mount Sinai. After being the only graduate to earn two Honors (Molecular Biology & Studio Art) at Wesleyan University, he completed his Ph.D. in Statistical Genomics and Postdoc in Multi-omic Software Development at Washington University in St. Louis. He has authored over 70 peer-reviewed publications including lead authorship in the top scientific journals, and is the author of the best-seller “Solve It Yourself.” Kuan was a co-founder/CEO of the startup DeepGene in grad school and currently serves as the Co-Founder and Chief Unboxer of OpenBoxScience.Org. A good day of his life typically involves great people, hikes, books, dark chocolate, bubble tea, surfing, tennis; and a 20-minute nap.

Dr. Pei-Hua (Candice) Chu is a board-certified veterinary clinical pathologist and an assistant professor at Texas A&M University. She earned her DVM degree from National Taiwan University and completed her PhD in veterinary pathology and residency training at Texas A&M University. Before her current role, she was an assistant professor of clinical pathology at the University of Pennsylvania. Dr. Chu’s research focuses on gene and microRNA expression related to chronic kidney disease, particularly the potential of urinary microRNAs as early biomarkers for dogs and cats. Her research integrates bioinformatics, digital cytology, and artificial intelligence in veterinary medicine. She recently published a review paper titled “ChatGPT in veterinary medicine: a practical guidance of generative artificial intelligence in clinics, education, and research” and was invited to speak at the American Veterinary Internal Medicine Forum and the Veterinary Information Network (VIN), the largest veterinary online community. n addition to her research, she teaches veterinary clinical pathology using innovative methods, including her popular Instagram page @Vet.Clin.Path.Professor.

Page updated

Google Sites

Report abuse